These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21898232)

  • 1. Combined lentiviral and RNAi technologies for the delivery and permanent silencing of the hsp25 gene.
    Kaur P; Nagaraja GM; Asea A
    Methods Mol Biol; 2011; 787():121-36. PubMed ID: 21898232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of RNA interference against cancer.
    Takeshita F; Ochiya T
    Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in RNAi-based antiviral therapeutics.
    Zhou J; Rossi JJ
    Methods Mol Biol; 2011; 721():67-75. PubMed ID: 21431679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNAi therapeutics: an update on delivery.
    Nguyen T; Menocal EM; Harborth J; Fruehauf JH
    Curr Opin Mol Ther; 2008 Apr; 10(2):158-67. PubMed ID: 18386228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells.
    Liu XX; Rocchi P; Qu FQ; Zheng SQ; Liang ZC; Gleave M; Iovanna J; Peng L
    ChemMedChem; 2009 Aug; 4(8):1302-10. PubMed ID: 19533723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
    Singh SK; Hajeri PB
    Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral vector-mediated RNA interference.
    Couto LB; High KA
    Curr Opin Pharmacol; 2010 Oct; 10(5):534-42. PubMed ID: 20620113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RNA silencing technology applied by lentiviral vectors in oncology.
    Sumimoto H; Kawakami Y
    Methods Mol Biol; 2010; 614():187-99. PubMed ID: 20225045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commercial potential of RNAi.
    Jain KK
    Mol Biosyst; 2006 Nov; 2(11):523-6. PubMed ID: 17216033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA interference therapy for glioblastoma.
    Guo D; Wang B; Han F; Lei T
    Expert Opin Biol Ther; 2010 Jun; 10(6):927-36. PubMed ID: 20415602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydrodynamic delivery protocols.
    Rychahou PG; Evers BM
    Methods Mol Biol; 2010; 623():189-95. PubMed ID: 20217552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA interference (RNAi) in hematology.
    Scherr M; Steinmann D; Eder M
    Ann Hematol; 2004 Jan; 83(1):1-8. PubMed ID: 14574462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.
    Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T
    Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The silent treatment: siRNAs as small molecule drugs.
    Dykxhoorn DM; Palliser D; Lieberman J
    Gene Ther; 2006 Mar; 13(6):541-52. PubMed ID: 16397510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference--significance and applications.
    Stanisławska J; Olszewski WL
    Arch Immunol Ther Exp (Warsz); 2005; 53(1):39-46. PubMed ID: 15761375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [RNA interference: from origins to a novel tool for gene silencing].
    Ortiz-Quintero B
    Rev Invest Clin; 2009; 61(5):412-27. PubMed ID: 20184102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.
    Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C
    Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.